Decrease in Irisin in Patients with Chronic Kidney Disease

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Wen, Ming Shien ^a   Wang, Chao Yung ^a   Lin, Shuei Liong ^b,c   Hung, Kuo Chun ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATININE; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IRISIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MUSCLE PROTEIN; NITROGEN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA; URIC ACID;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENERGY EXPENDITURE; ENZYME IMMUNOASSAY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; MALE; PATIENT ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; UREA NITROGEN BLOOD LEVEL; UREMIA; WESTERN BLOTTING;

CASE-CONTROL STUDIES; CREATININE; DEMOGRAPHY; FEMALE; FIBRONECTINS; HUMANS; INDICAN; MALE; MIDDLE AGED; MUSCLE CELLS; MUSCLE, SKELETAL; RENAL INSUFFICIENCY, CHRONIC;

EID: 84877129604     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064025     Document Type: Article

References (31)

1. Avesani CM, Kamimura MA, Cuppari L, (2011) Energy expenditure in chronic kidney disease patients. J Ren Nutr 21: 27-30 doi:10.1053/j.jrn.2010.10.013.
2. Kamimura MA, Draibe SA, Avesani CM, Canziani MEF, Colugnati FAB, et al. (2007) Resting energy expenditure and its determinants in hemodialysis patients. Eur J Clin Nutr 61: 362-367 doi:10.1038/sj.ejcn.1602516.
3. Brenner I, Brohart K, (2008) Weekly energy expenditure and quality of life in hemodialysis patients. CANNT J 18: 36-40.
4. Avesani CM, Draibe SA, Kamimura MA, Dalboni MA, Colugnati FAB, et al. (2004) Decreased resting energy expenditure in non-dialysed chronic kidney disease patients. Nephrol Dial Transplant 19: 3091-3097 doi:10.1093/ndt/gfh547.
5. Levey AS, Coresh J, (2012) Chronic kidney disease. Lancet 379: 165-180 doi:10.1016/S0140-6736(11)60178-5.
6. Schneeweiss B, Graninger W, Stockenhuber F, Druml W, Ferenci P, et al. (1990) Energy metabolism in acute and chronic renal failure. Am J Clin Nutr 52: 596-601.
7. Kuhlmann U, Schwickardi M, Trebst R, Lange H, (2001) Resting metabolic rate in chronic renal failure. J Ren Nutr 11: 202-206.
8. Stengel B, (2010) Chronic kidney disease and cancer: a troubling connection. J Nephrol 23: 253-262.
9. Zurlo F, Larson K, Bogardus C, Ravussin E, (1990) Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Clin Invest 86: 1423-1427 doi:10.1172/JCI114857.
10. Wang AY-M, (2011) Energy intake and energy expenditure profiles in peritoneal dialysis patients. J Ren Nutr 21: 31-34 doi:10.1053/j.jrn.2010.10.018.
11. Panesar A, Agarwal R, (2003) Resting energy expenditure in chronic kidney disease: relationship with glomerular filtration rate. Clin Nephrol 59: 360-366.
12. Kamimura MA, Avesani CM, Bazanelli AP, Baria F, Draibe SA, et al. (2011) Are prediction equations reliable for estimating resting energy expenditure in chronic kidney disease patients? Nephrol Dial Transplant 26: 544-550 doi:10.1093/ndt/gfq452.
13. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, et al. (2012) A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481: 463-468 doi:10.1038/nature10777.
14. Villarroya F, (2012) Irisin, turning up the heat. Cell Metab 15: 277-278 doi:10.1016/j.cmet.2012.02.010.
15. Kelly DP, (2012) Medicine. Irisin, light my fire. Science 336: 42-43 doi:10.1126/science.1221688.
16. Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, et al. (2012) FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metab Clin Exp. doi:10.1016/j.metabol.2012.09.002.
17. Matsuki N, Takanohashi A, Boffi FM, Inanami O, Kuwabara M, et al. (1999) Hydroxyl radical generation and lipid peroxidation in C2C12 myotube treated with iodoacetate and cyanide. Free Radic Res 31: 1-8.
18. Holzer M, Birner-Gruenberger R, Stojakovic T, El-Gamal D, Binder V, et al. (2011) Uremia alters HDL composition and function. J Am Soc Nephrol 22: 1631-1641 doi:10.1681/ASN.2010111144.
19. Verma A, Anavekar NS, Meris A, Thune JJ, Arnold JMO, et al. (2007) The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study. J Am Coll Cardiol 50: 1238-1245 doi:10.1016/j.jacc.2007.06.018.
20. Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H, (2012) Cardiorenal syndrome: the emerging role of protein-bound uremic toxins. Circ Res 111: 1470-1483 doi:10.1161/CIRCRESAHA.112.278457.
21. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, et al. (2009) Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 4: 1551-1558 doi:10.2215/CJN.03980609.
22. Lekawanvijit S, Kompa AR, Manabe M, Wang BH, Langham RG, et al. (2012) Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PLoS ONE 7: e41281 doi:10.1371/journal.pone.0041281.
23. Chen J, Muntner P, Hamm LL, Fonseca V, Batuman V, et al. (2003) Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 14: 469-477.
24. Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T, (2005) Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 45: 275-280.
25. Thompson PD, Rader DJ, (2001) Does exercise increase HDL cholesterol in those who need it the most? Arterioscler Thromb Vasc Biol 21: 1097-1098.
26. Durstine JL, Miller W, Farrell S, Sherman WM, Ivy JL, (1983) Increases in HDL-cholesterol and the HDL/LDL cholesterol ratio during prolonged endurance exercise. Metab Clin Exp 32: 993-997.
27. Couillard C, Després JP, Lamarche B, Bergeron J, Gagnon J, et al. (2001) Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study. Arterioscler Thromb Vasc Biol 21: 1226-1232.
28. Badimon L, Vilahur G, (2012) LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos. Ann N Y Acad Sci 1254: 18-32 doi:10.1111/j.1749-6632.2012.06480.x.
29. Chyu K-Y, Peter A, Shah PK, (2011) Progress in HDL-based therapies for atherosclerosis. Curr Atheroscler Rep 13: 405-412 doi:10.1007/s11883-011-0189-9.
30. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, et al. (2000) Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 102: 1893-1900.
31. Degoma EM, Rader DJ, (2011) Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol 8: 266-277 doi:10.1038/nrcardio.2010.200.